Arrhythmic effects of Epac‐mediated ryanodine receptor activation in Langendorff‐perfused murine hearts are associated with reduced conduction velocity
Open Access
- 19 May 2017
- journal article
- research article
- Published by Wiley in Clinical and Experimental Pharmacology and Physiology
- Vol. 44 (6) , 686-692
Abstract
Summary: Recent papers have attributed arrhythmic substrate in murineRyR2‐P2328Shearts to reduced action potential (AP) conduction velocities (CV), reflecting acute functional inhibition and/or reduced expression of sodium channels. We explored for acute effects of direct exchange protein directly activated bycAMP(Epac)‐mediated ryanodine receptor‐2 (RyR2) activation on arrhythmic substrate andCV. Monophasic action potential (MAP) recordings demonstrated that initial steady (8 Hz) extrinsic pacing elicited ventricular tachycardia (VT) in 0 of 18 Langendorff‐perfused wild‐type mouse ventricles before pharmacological intervention. The Epac activator 8‐CPT(8‐(4‐chlorophenylthio)‐2′‐O‐methyladenosine‐3′,5′‐cyclic monophosphate) (VTin 1 of 7 hearts), and the RyR2 blocker dantrolene, either alone (0 of 11) or with 8‐CPT(0 of 9) did not then increaseVTincidence (P>.05). Both progressively increased pacing rates and programmed extrasystolic (S2) stimuli similarly produced noVTin untreated hearts (n=20 and n=9 respectively). 8‐CPTchallenge then increasedVTincidences (5 of 7 and 4 of 8 hearts respectively;P<.05). However, dantrolene, whether alone (0 of 10 and 1 of 13) or combined with 8‐CPT(0 of 10 and 0 of 13) did not increaseVTincidence relative to those observed in untreated hearts (P>.05). 8‐CPTbut not dantrolene, whether alone or combined with 8‐CPT, correspondingly increasedAPlatencies (1.14±0.04 (n=7), 1.04±0.03 (n=10), 1.09±0.05 (n=8) relative to respective control values). In contrast,APdurations, conditions for 2:1 conduction block and ventricular effective refractory periods remained unchanged throughout. We thus demonstrate for the first time that acute RyR2 activation reversibly inducesVTin specific association with reducedCV.Keywords
Funding Information
- Wellcome Trust (105727/Z/14/Z)
- Medical Research Council (MR/M001288/1)
- British Heart Foundation (PG/08/116)
This publication has 35 references indexed in Scilit:
- Loss of Nav1.5 expression and function in murine atria containing the RyR2-P2328S gain-of-function mutationCardiovascular Research, 2013
- Ca2+/Calmodulin-dependent Protein Kinase II (CaMKII) Regulates Cardiac Sodium Channel NaV1.5 Gating by Multiple Phosphorylation SitesJournal of Biological Chemistry, 2012
- Dantrolene prevents arrhythmogenic Ca2+release in heart failureAmerican Journal of Physiology-Heart and Circulatory Physiology, 2012
- Dantrolene rescues arrhythmogenic RYR2 defect in a patient‐specific stem cell model of catecholaminergic polymorphic ventricular tachycardiaEMBO Molecular Medicine, 2012
- Dantrolene, a Therapeutic Agent for Malignant Hyperthermia, Markedly Improves the Function of Failing Cardiomyocytes by Stabilizing Interdomain Interactions Within the Ryanodine ReceptorJACC, 2009
- Physiological consequences of the P2328S mutation in the ryanodine receptor (RyR2) gene in genetically modified murine heartsActa Physiologica, 2008
- Cyclic nucleotide analogs as probes of signaling pathwaysNature Methods, 2008
- The cAMP binding protein Epac modulates Ca2+ sparks by a Ca2+/calmodulin kinase signalling pathway in rat cardiac myocytesThe Journal of Physiology, 2007
- Cell physiology of cAMP sensor EpacThe Journal of Physiology, 2006
- Electrophysiologic Mechanisms for Ventricular Arrhythmias in Left Ventricular Dysfunction: Electrolytes, Catecholamines and DrugsThe Journal of Clinical Pharmacology, 1991